Third Harmonic Bio to Join Upcoming Investor Conferences

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company listed on Nasdaq (THRD), is pioneering advancements in the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. On August 26, 2024, the San Francisco-based company revealed that its CEO, Natalie Holles, will be participating in two significant upcoming conferences. The first event is the Morgan Stanley 22nd Healthcare Conference, scheduled for Wednesday, September 4, 2024, at 9:15 a.m. ET. The second is the Stifel 2024 Virtual Immunology and Inflammation Summit, which will take place on Wednesday, September 18, 2024, at 9:00 a.m. ET. Both events will feature live audio webcasts accessible through the Investors & Media section of the Third Harmonic Bio website. Recordings of these sessions will be available for 90 days post-event.

Third Harmonic Bio is devoted to developing innovative, highly selective small-molecule inhibitors of KIT, a cell surface receptor crucial for regulating mast cell functions and survival. Mast cells are pivotal in the body's inflammatory response, and their dysregulation can lead to various inflammatory diseases. KIT inhibition has shown promise in early clinical trials, suggesting it could transform the treatment of many mast-cell-mediated conditions. The company's approach centers on creating a titratable, oral small molecule inhibitor that can be finely tuned to achieve the best therapeutic effect.

The company's leading product candidate, THB335, exemplifies this novel approach. THB335 is an oral, small molecule inhibitor that is currently undergoing Phase 1 clinical trials. This candidate is designed to be titratable, allowing for precise dosage adjustments, which is seen as a significant advantage in managing inflammatory diseases mediated by mast cells. This development is in line with Third Harmonic Bio's mission to harness the power of selective KIT inhibition to address unmet medical needs in inflammatory disease treatment.

Third Harmonic Bio's strategy underscores the broader trend in the biopharmaceutical industry towards developing targeted therapies that offer increased efficacy and decreased side effects. The focus on KIT inhibition is particularly noteworthy because it addresses the root cause of mast-cell-mediated diseases, potentially providing a more effective treatment option compared to existing therapies that may only alleviate symptoms.

The company's participation in these high-profile conferences indicates its commitment to engaging with the broader medical and scientific community. By sharing insights and updates on their progress, Third Harmonic Bio aims to foster a deeper understanding of their innovative approaches and the potential impact of their therapies.

In summary, Third Harmonic Bio is at the forefront of biopharmaceutical innovation, specifically in the realm of inflammatory diseases. The company is progressing with its lead candidate, THB335, and continues to explore the therapeutic potential of KIT inhibition. With upcoming presentations at major conferences, Third Harmonic Bio is poised to share its vision and advancements with a wider audience, highlighting its role in shaping the future of inflammatory disease treatment.